Valentis Inc. missed its endpoint in a Phase II study of its lead product, Deltavasc, and watched its stock plummet after reporting the news Wednesday. But the trial might have uncovered a product to replace Deltavasc at the top of Valentis' pipeline, which could allow for a regulatory filing along the same timeline. (BioWorld Today) Read More
